BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31665212)

  • 1. Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.
    Raghu VK; Binion DG; Smith KJ
    Am J Clin Nutr; 2020 Jan; 111(1):141-148. PubMed ID: 31665212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of teduglutide in adult patients with short bowel syndrome - a European socioeconomic perspective.
    Walter E; Dawoud C; Hütterer E; Stift A; Harpain F
    Am J Clin Nutr; 2024 May; 119(5):1187-1199. PubMed ID: 38431119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of teduglutide in pediatric patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.
    Raghu VK; Rudolph JA; Smith KJ
    Am J Clin Nutr; 2021 Jan; 113(1):172-178. PubMed ID: 33021637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome.
    Gattini D; Belza C; Kraus R; Avitzur Y; Ungar WJ; Wales PW
    Clin Nutr; 2023 Dec; 42(12):2363-2371. PubMed ID: 37862822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Center Experience with the Use of Teduglutide in Adult Patients with Short Bowel Syndrome.
    Lam K; Schwartz L; Batisti J; Iyer KR
    JPEN J Parenter Enteral Nutr; 2018 Jan; 42(1):225-230. PubMed ID: 29505151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
    Jeppesen PB; Pertkiewicz M; Forbes A; Pironi L; Gabe SM; Joly F; Messing B; Loth S; Youssef NN; Heinze H; Berghöfer P
    Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.
    O'Keefe SJ; Jeppesen PB; Gilroy R; Pertkiewicz M; Allard JP; Messing B
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):815-23.e1-3. PubMed ID: 23333663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.
    Jeppesen PB; Gabe SM; Seidner DL; Lee HM; Olivier C
    Gastroenterology; 2018 Mar; 154(4):874-885. PubMed ID: 29174926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study.
    Joly F; Seguy D; Nuzzo A; Chambrier C; Beau P; Poullenot F; Thibault R; Armengol Debeir L; Layec S; Boehm V; Lallemand J; Quilliot D; Schneider SM
    Clin Nutr; 2020 Sep; 39(9):2856-2862. PubMed ID: 31932048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with teduglutide treatment for short bowel syndrome in clinical practice.
    Pevny S; Maasberg S; Rieger A; Karber M; Blüthner E; Knappe-Drzikova B; Thurmann D; Büttner J; Weylandt KH; Wiedenmann B; Müller VA; Bläker H; Pascher A; Pape UF
    Clin Nutr; 2019 Aug; 38(4):1745-1755. PubMed ID: 30145039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.
    Jeppesen PB; Gilroy R; Pertkiewicz M; Allard JP; Messing B; O'Keefe SJ
    Gut; 2011 Jul; 60(7):902-14. PubMed ID: 21317170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teduglutide for treatment of adult patients with short bowel syndrome.
    Billiauws L; Bataille J; Boehm V; Corcos O; Joly F
    Expert Opin Biol Ther; 2017 May; 17(5):623-632. PubMed ID: 28293969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Polish Intestinal Failure Centres' consensus on the use of teduglutide for the treatment of short bowel syndrome.
    Klek S; Kunecki M; Sobocki J; Matysiak K; Karwowska K; Urbanowicz K
    Nutrition; 2017 Jun; 38():28-33. PubMed ID: 28526379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Management of Patients With Parenteral Nutrition-Dependent Short Bowel Syndrome During Teduglutide Therapy.
    Compher C; Boullata JI; Pickett-Blakely O; Schiavone P; Stoner N; Kinosian BP
    JPEN J Parenter Enteral Nutr; 2016 Nov; 40(8):1183-1190. PubMed ID: 26111832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-Label Teduglutide Therapy in Non-intestinal Failure Patients with Chronic Malabsorption.
    George AT; Li BH; Carroll RE
    Dig Dis Sci; 2019 Jun; 64(6):1599-1603. PubMed ID: 30730014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure.
    Chen K; Mu F; Xie J; Kelkar SS; Olivier C; Signorovitch J; Jeppesen PB
    JPEN J Parenter Enteral Nutr; 2020 Jan; 44(1):119-128. PubMed ID: 31006876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome.
    Tappenden KA; Edelman J; Joelsson B
    J Clin Gastroenterol; 2013 Aug; 47(7):602-7. PubMed ID: 23426461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.
    Iyer KR; Kunecki M; Boullata JI; Fujioka K; Joly F; Gabe S; Pape UF; Schneider SM; Virgili Casas MN; Ziegler TR; Li B; Youssef NN; Jeppesen PB
    JPEN J Parenter Enteral Nutr; 2017 Aug; 41(6):946-951. PubMed ID: 27875291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of teduglutide treatment for chronic intestinal failure - Insights from a national, multi-centric patient home-care service program.
    Greif S; Maasberg S; Wehkamp J; Fusco S; Zopf Y; Herrmann HJ; Lamprecht G; Jacob T; Schiefke I; von Websky MW; Büttner J; Blüthner E; Tacke F; Pape UF
    Clin Nutr ESPEN; 2022 Oct; 51():222-230. PubMed ID: 36184208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.
    Thymann T; Stoll B; Mecklenburg L; Burrin DG; Vegge A; Qvist N; Eriksen T; Jeppesen PB; Sangild PT
    J Pediatr Gastroenterol Nutr; 2014 Jun; 58(6):694-702. PubMed ID: 24399211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.